Compare Procter & Gamble Co (PG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Tango Therapeutics Inc. — how do they compare? Procter & Gamble Co trades at $157.69 (market cap $355.46B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Procter & Gamble Co is far larger — about 94.8× Tango Therapeutics Inc.'s market cap, and Procter & Gamble Co pays a 2.85% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 132 Days and Tango Therapeutics Inc. for 0 Days on average.
| PG | TNGX | |
|---|---|---|
Market Cap | $355.46B | $3.75B |
Volume | 5,731,171 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $32.90 |
52-Week Low | $138.10 | $7.50 |
Typical Hold Time | 132 Days | 0 Days |
Enterprise Value | $381.30B | $2.77B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $156.57, up 2.2% today, near its consensus price target of $160.13. The stock shows bullish technical signals with strong moving average support and has beaten earnings estimates for three consecutive quarters. Revenue reached $84.28B in 2025 with a net income margin of 18.44%, while the company maintains a robust dividend history and positive cash flow trends.
PG offers stable growth with high profitability and shareholder returns, but premium valuation multiples pose near-term upside limitations. Risks include soft demand outlook and competitive pressures, though analyst consensus remains bullish with 53% buy ratings. The stock's resilience in volatile markets supports its appeal for dividend-focused investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
